140 related articles for article (PubMed ID: 9341910)
1. Synthesis of gonadotropin-releasing hormone III analogs. Structure-antitumor activity relationships.
Mezö I; Lovas S; Pályi I; Vincze B; Kálnay A; Turi G; Vadász Z; Seprödi J; Idei M; Tóth G; Gulyás E; Otvös F; Mák M; Horváth JE; Teplán I; Murphy RF
J Med Chem; 1997 Oct; 40(21):3353-8. PubMed ID: 9341910
[TBL] [Abstract][Full Text] [Related]
2. Effect of gonadotropin-releasing hormone analogs and their conjugates on gonadotropin-releasing hormone receptor--positive human cancer cell lines.
Pályi I; Vincze B; Kálnay A; Turi G; Mezõ I; Teplán I; Seprõdi J; Pató J; Móra M
Cancer Detect Prev; 1996; 20(2):146-52. PubMed ID: 8706040
[TBL] [Abstract][Full Text] [Related]
3. Peptides and antitumor activity. Development and investigation of some peptides with antitumor activity.
Teplán I
Acta Biol Hung; 2000; 51(1):1-29. PubMed ID: 10866357
[TBL] [Abstract][Full Text] [Related]
4. Structure-activity study on the LH- and FSH-releasing and anticancer effects of gonadotropin-releasing hormone (GnRH)-III analogs.
Kovács M; Vincze B; Horváth JE; Seprodi J
Peptides; 2007 Apr; 28(4):821-9. PubMed ID: 17289216
[TBL] [Abstract][Full Text] [Related]
5. Is lGnRH-III the most potent GnRH analog containing only natural amino acids that specifically inhibits the growth of human breast cancer cells?
Herédi-Szabó K; Murphy RF; Lovas S
J Pept Sci; 2006 Nov; 12(11):714-20. PubMed ID: 16967433
[TBL] [Abstract][Full Text] [Related]
6. Structure, enzymatic stability and antitumor activity of sea lamprey GnRH-III and its dimer derivatives.
Mezo G; Czajlik A; Manea M; Jakab A; Farkas V; Majer Z; Vass E; Bodor A; Kapuvári B; Boldizsár M; Vincze B; Csuka O; Kovács M; Przybylski M; Perczel A; Hudecz F
Peptides; 2007 Apr; 28(4):806-20. PubMed ID: 17254668
[TBL] [Abstract][Full Text] [Related]
7. Importance of the central region of lamprey gonadotropin-releasing hormone III in the inhibition of breast cancer cell growth.
Herédi-Szabó K; Lubke J; Toth G; Murphy RF; Lovas S
Peptides; 2005 Mar; 26(3):419-22. PubMed ID: 15652648
[TBL] [Abstract][Full Text] [Related]
8. Enhanced cellular uptake and in vitro antitumor activity of short-chain fatty acid acylated daunorubicin-GnRH-III bioconjugates.
Hegedüs R; Manea M; Orbán E; Szabó I; Kiss E; Sipos E; Halmos G; Mező G
Eur J Med Chem; 2012 Oct; 56():155-65. PubMed ID: 22967796
[TBL] [Abstract][Full Text] [Related]
9. Structure-activity studies of lGnRH-III through rational amino acid substitution and NMR conformational studies.
Pappa EV; Zompra AA; Diamantopoulou Z; Spyranti Z; Pairas G; Lamari FN; Katsoris P; Spyroulias GA; Cordopatis P
Biopolymers; 2012; 98(6):525-34. PubMed ID: 23203758
[TBL] [Abstract][Full Text] [Related]
10. Design of biologically active, conformationally constrained GnRH antagonists.
Struthers RS; Tanaka G; Koerber SC; Solmajer T; Baniak EL; Gierasch LM; Vale W; Rivier J; Hagler AT
Proteins; 1990; 8(4):295-304. PubMed ID: 2091022
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of growth and proliferation of EcRG293 cell line expressing high-affinity gonadotropin-releasing hormone (GnRH) receptor under the control of an inducible promoter by GnRH agonist (D-Lys6)GnRH and antagonist (Antide).
Kakar SS
Cancer Res; 1998 Oct; 58(20):4558-60. PubMed ID: 9788600
[TBL] [Abstract][Full Text] [Related]
12. Synthesis of GnRH analogs having direct antitumor and low LH-releasing activity.
Mezô I; Seprôdi J; Vincze B; Pályi I; Kéri G; Vadász Z; Tóth G; Kovács M; Koppán M; Horváth JE; Kálnay A; Teplán I
Biomed Pept Proteins Nucleic Acids; 1996; 2(2):33-40. PubMed ID: 9346824
[TBL] [Abstract][Full Text] [Related]
13. Chymotrypsin-catalyzed fragment coupling synthesis of GnRH-analogs.
Hänsicke A; Krause E; Bienert M; Schmidt M; Kobert S; Schellenberger V; Jakubke HD; Kaufmann KD
Biomed Biochim Acta; 1991; 50(10-11):S201-4. PubMed ID: 1820046
[TBL] [Abstract][Full Text] [Related]
14. Synthesis, in vitro stability, and antiproliferative effect of d-cysteine modified GnRH-doxorubicin conjugates.
Li S; Zhao H; Chang X; Wang J; Zhao E; Yin Z; Mao X; Deng S; Hao T; Wang H; Yang Y
J Pept Sci; 2019 Jan; 25(1):e3135. PubMed ID: 30467919
[TBL] [Abstract][Full Text] [Related]
15. Synthesis, conformation, biodistribution, and hormone-related in vitro antitumor activity of a gonadotropin-releasing hormone antagonist-branched polypeptide conjugate.
Mezö G; Mezö I; Pimm MV; Kajtár J; Seprödi J; Teplán I; Kovács M; Vincze B; Pályi I; Idei M; Szekerke M; Hudecz F
Bioconjug Chem; 1996; 7(6):642-50. PubMed ID: 8950483
[TBL] [Abstract][Full Text] [Related]
16. Development of novel 68Ga- and 18F-labeled GnRH-I analogues with high GnRHR-targeting efficiency.
Schottelius M; Berger S; Poethko T; Schwaiger M; Wester HJ
Bioconjug Chem; 2008 Jun; 19(6):1256-68. PubMed ID: 18510351
[TBL] [Abstract][Full Text] [Related]
17. A novel computer modeling approach to the structures of small bioactive peptides: the structure of gonadotropin releasing hormone.
Gupta HM; Talwar GP; Salunke DM
Proteins; 1993 May; 16(1):48-56. PubMed ID: 8497483
[TBL] [Abstract][Full Text] [Related]
18. Evidence for hormone-responsive cleavage of gonadotropin-releasing hormone by the plasma membrane of ovarian cancer cells.
Imai A; Iida K; Furui T; Tamaya T
Int J Oncol; 2002 May; 20(5):987-92. PubMed ID: 11956594
[TBL] [Abstract][Full Text] [Related]
19. Gonadotropin-releasing hormone and ovarian cancer: a functional and mechanistic overview.
So WK; Cheng JC; Poon SL; Leung PC
FEBS J; 2008 Nov; 275(22):5496-511. PubMed ID: 18959739
[TBL] [Abstract][Full Text] [Related]
20. lGnRH-III -- a promising candidate for anticancer drug development.
Manea M; Mező G
Protein Pept Lett; 2013 Apr; 20(4):439-49. PubMed ID: 23016589
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
